Prescribing guide
Rystiggo (rozanolixizumab-noli)Treatment cycles, administration, monitoring and prior authorization criteria for gMGFor prescribers and their offices treating generalized myasthenia gravis: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. Prior authorization, ONWARD Start Form with antibody report, healthcare provider administration only (office, infusion center, hospital outpatient or home infusion nurse), limited specialty pharmacy network or buy and bill, and no active infection on each dose day.
Example PA threshold
FEP example: age 18 or older, anti-AChR or anti-MuSK positive, MGFA II to IVa, MG-ADL 3 or higher with 3 or more non-ocular points or QMG above 9, IgG 5.5g/L or higher, one failed AChE inhibitor or immunosuppressant.
Monitoring
Hypersensitivity observation during and for 15 minutes after each infusion; infection check before each dose; vaccine review before each new cycle; work up new severe headache for aseptic meningitis; no scheduled labs.
Support line
ONWARD, 1-844-ONWARD1 (1-844-669-2731), Monday to Friday 8 AM to 8 PM ET, Start Form fax 1-833-329-8221, Care Coordinator, copay as little as $0 per dose for commercial plans, Patient Assistance Program up to 12 months.
Give your patient their plan
A one-page handout for starting Rystiggo, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/rystiggoBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in ONWARD | Fax the Start Form to 1-833-FAX-UCB1 (1-833-329-8221), email ucbonward@rxallcare.com, or enroll online at ONWARDhcp-enroll-RYSTIGGO.com. Attach clinical notes, MGFA class, MG-ADL score, anti-AChR and/or anti-MuSK lab reports and the medication list. | ONWARD Start Form |
| Patient signature | The patient signs the Patient Authorization pages (4 and 5); PAP applicants also consent to a consumer report for income estimation. ONWARD's call may display ONWARD, 1-844-669-2731 or an 833 area code. | ONWARD Start Form |
| Write the prescription | Select the weight band and record the weight date: 1 vial (420mg/3mL, 560mg/4mL or 840mg/6mL) by SC infusion once weekly for 6 weeks, quantity 6 vials. The form also authorizes home nurse visits and supplies. | ONWARD Start Form |
| Specialty pharmacy route | Limited network: CVS Specialty, KabaFusion, Optum Infusion, SoleoHealth, and Alivia Health (Puerto Rico only). | ONWARD Start Form |
| Buy and bill route | Authorized specialty distributors include ASD Healthcare, Besse Medical, Oncology Supply, BioCareSD, CuraScript SD, Cardinal Health SPD and Metro Medical, and McKesson. | How to acquire |
| Benefit | UCB's coding guide states Rystiggo is administered under the medical benefit, in the office, infusion center, hospital outpatient department or the home by an authorized home care partner. | Coding and billing guide |
| List price | WAC as of July 2026: $6,421 (280mg/2mL), $9,632 (420mg/3mL), $12,842 (560mg/4mL), $19,264 (840mg/6mL) per vial; $22.93 per mg. | How to acquire |
| Coding | HCPCS J9333, 1mg per unit, with JZ when nothing is discarded. CPT 96369 for the initial SC infusion up to 1 hour; some payers may require 96372 or 96401 for infusions under 15 minutes. | Coding and billing guide |
| Copay program | Commercial insurance only; excludes Medicare (Part D and Medigap), Medicaid, state programs, TRICARE, VA and DoD. Massachusetts, Minnesota and Rhode Island residents get no copay support for administration costs. PAP may supply Rystiggo at no cost for up to 12 months. | UCB cost page |
| Self-administration | Not in the US label. On January 31, 2025 UCB announced a positive CHMP opinion, which it called EU approval, for self-administration by syringe pump or manual push after training. | UCB release |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, October 1, 2026. Approval six months at first, then 12 months at a time if the MG-ADL or QMG score fell 2 points or more, with no unacceptable side effects. This policy was last reviewed on September 17, 2026 and cites the December 2025 Rystiggo label, so it matches the current approved use. In September 2025 FEP dropped its earlier rule requiring 2 failed treatments and added the QMG score as an option. It sets no minimum gap between cycles of its own. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Generalized myasthenia gravis, age 18 or older, with anti-AChR or anti-MuSK autoantibodies | Antibody result with date | FEP Blue policy |
| Severity | MGFA clinical class II to IVa | Class recorded in the note | FEP Blue policy |
| Baseline score | MG-ADL total 3 or more with at least 3 points from non-ocular items, or QMG total above 9 | Dated score sheet | FEP Blue policy |
| IgG | Serum IgG 5.5g/L or higher | Serum IgG with date | FEP Blue policy |
| Prior therapy | Inadequate response, intolerance or contraindication to one of: AChE inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide | Agent, dose, dates and outcome | FEP Blue policy |
| Vaccines | Not given concurrently with live or live-attenuated vaccines | Immunization history | FEP Blue policy |
| Renewal | MG-ADL or QMG down 2 points or more from baseline, no unacceptable toxicity, no concurrent live vaccines; first approval 6 months, renewals 12 months | Current score against baseline | FEP Blue policy |
| Policy history | September 2025: FEP removed the double step requirement and added QMG as an alternative score | Check any denial against the October 2026 version | FEP Blue policy |
Rystiggo dosing and titration
| When | Label | Source |
|---|---|---|
| Cycle | Under 50kg 420mg (3mL); 50kg to under 100kg 560mg (4mL); 100kg and above 840mg (6mL). SC infusion by pump at a constant rate up to 20mL/hour, once weekly for 6 weeks. | FDA label |
| Pump and set | Pump with pre-settable volume (vials hold overfill for priming); occlusion alarm at maximum; tubing 61cm or shorter; infusion set needle 26 gauge or larger. Do not flush the line after the infusion. | FDA label |
| Preparation | Vials to room temperature about 30 minutes, no heating devices, do not shake. Fill the syringe with transfer needles; infuse within 4 hours of puncture and immediately after priming. Single use, no preservative. | FDA label |
| Site | Lower right or lower left abdomen below the navel; avoid tender, bruised, red or hard skin, tattoos, scars and stretch marks; rotate sites. | FDA label |
| Next cycle | Administer subsequent cycles based on clinical evaluation. Safety of starting sooner than 63 days from the previous cycle start is not established. Extension: mean 4 cycles a year (range 1 to 7); median 98 days between starts for patients with 4 cycles. | FDA label |
| Missed dose | May be given up to 4 days after the scheduled time point; then resume the original schedule until the cycle is complete. | FDA label |
| Storage | 2°C to 8°C in the carton, do not freeze or shake. Room temperature up to 25°C allowed once, for up to 20 days; write the discard date on the carton and do not return to the refrigerator. The June 2024 and December 2025 (S-007) FDA label PDFs say 30 days. | FDA label |
| Immunogenicity | ADA 37% and neutralizing antibodies 21% after one cycle in Study 1, with up to 60% lower troughs in ADA-positive patients; no clinically meaningful effect on efficacy or safety apparent. | FDA label |
Monitoring the Rystiggo label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each infusion | Hypersensitivity: angioedema, rash | Observe during and for 15 minutes after; stop the infusion and treat if a reaction occurs. Trial reactions came 1 day to 2 weeks after dosing; 1 discontinuation | FDA label |
| Before each dose | Active infection | Delay until resolved; if serious infection occurs, treat and consider withholding. Across studies 48% had infections (URTI 17%, COVID-19 14%, UTI 9%, herpes simplex 6%), serious 4%, 3 fatal pneumonias, 6 discontinuations | FDA label |
| Any time | Headache and aseptic meningitis | Headache 44% against 19% placebo, severe 5.3% against 0. Aseptic meningitis in 1 gMG and 2 other-disease patients, all hospitalized and discontinued; work up per standard of care | FDA label |
| New headache type | Payer framing | FEP's policy asks prescribers to evaluate new-onset headache type with lumbar puncture for CSF analysis and hold the dose accordingly | FEP Blue policy |
| Before each new cycle | Vaccination status | Evaluate age-appropriate vaccines per immunization guidelines; live or live-attenuated vaccines not recommended during treatment | FDA label |
| 1 to 3 days after a dose | Administration site reactions | 8% against 3% placebo in Study 1 | FDA label |
| Postmarketing | Herpes zoster | Added to section 6.2 in December 2025 | FDA letter |
Rystiggo drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Monitor closely | FcRn-binding agents: immunoglobulin products, monoclonal antibodies, antibody derivatives with a human IgG Fc domain; exposure and effect may fall. If long-term concomitant use is essential, consider discontinuing Rystiggo | FDA label |
| CYP450 | Not metabolized by CYP450; CYP-mediated interactions unlikely; no clinical interaction studies | FDA label |
| Live vaccines | Not recommended during treatment; vaccine response during treatment not studied | FDA label |
| Renal and hepatic | No dose adjustment in renal impairment (population PK at eGFR 38 to 161); hepatic impairment not expected to affect PK, not studied | FDA label |
| Pregnancy | May cause fetal harm based on monkey data (embryonic death, reduced weight and impaired immune function in offspring); registry via UCBCares 1-844-599-CARE (2273) or ucbcares@ucb.com; MGBase registry for HCPs | FDA label |
| Lactation and pediatrics | No human milk data; safety and effectiveness in pediatric patients not established | FDA label |
| Contraindicated | None | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for a positive AChR or MuSK antibody test, a symptom score, an IgG level and one earlier treatment that did not work. If a request is denied, UCB says your healthcare provider starts the appeal, and your Care Coordinator keeps you updated.
- The prescription went to a pharmacy outside the networkRystiggo comes through a limited network of specialty pharmacies, including CVS Specialty, KabaFusion, Optum Infusion and SoleoHealth. Clinics can also buy it from an authorized distributor and bill your plan, so this is a routing question rather than a denial.
- Home infusion is not coveredUCB says home infusions with a nurse depend on your insurance coverage. An infusion center, doctor's office or hospital clinic may still be covered, and ONWARD's Care Coordinator can help find one near you.
- A copay you cannot payWith commercial insurance, UCB's copay program may bring the cost as low as $0 per dose. Medicare, Medicaid, TRICARE, VA and other government plans are excluded by its terms. Eligible patients may get Rystiggo free for up to 12 months through the Patient Assistance Program.
- You live in Massachusetts, Minnesota or Rhode IslandThe copay program's terms exclude residents of these 3 states from help with administration costs. The clinic's infusion fee may therefore fall on you, so ask ONWARD about other options.
- You do not have AChR or MuSK antibodiesThe label covers only adults who test positive for one of these 2 antibodies, and the FEP policy requires the same. Other treatment choices are a conversation for your neurologist.
- Renewal refused after the first approvalThe FEP policy below approves 6 months first, then renews for 12 months if the MG-ADL or QMG score dropped 2 points or more. Keeping the score sheets from cycle 1 makes that renewal easier for the office.
ONWARD
- A medically trained ONWARD Care Coordinator personally assigned to you, who does not give medical advice
- Help reviewing insurance coverage and potential financial assistance options, even if you are uninsured
- Tools and resources to help you start and continue your prescribed treatment
- Information on symptom tracking and ongoing treatment support
- Sign-up through your doctor, a Start Form from ucbONWARD.com, or a call to 1-844-ONWARD-1
Questions prescribers' offices ask about Rystiggo
What is the Rystiggo dose for generalized myasthenia gravis?
420mg (3mL) under 50kg, 560mg (4mL) from 50kg to under 100kg, and 840mg (6mL) at 100kg or more, by SC infusion pump at up to 20mL/hour once weekly for 6 weeks, per the label revised December 2025 (DailyMed version effective October 23, 2026). In Study 1, weight-tiered doses equivalent to about 7mg/kg and about 10mg/kg gave the same MG-ADL change (-3.4 points). Later cycles follow clinical evaluation.
How soon can the next Rystiggo cycle start?
The December 2025 label says the safety of starting a cycle sooner than 63 days from the start of the previous cycle has not been established, and otherwise leaves timing to clinical evaluation. That was the protocol minimum in the extension study, where patients averaged 4 cycles a year (range 1 to 7) and those with 4 cycles had a median 98 days between starts. The FEP policy shown here adds no interval rule of its own.
Can patients self-administer Rystiggo in the US?
No: the December 2025 US label says Rystiggo should only be prepared and infused by a healthcare provider, and the carton reads 'To be administered by a healthcare provider only.' Home infusion by a nurse is available subject to insurance, and UCB's Start Form includes a home nurse order. Self-administration by pump or manual push after training received a positive CHMP opinion in the EU (UCB, January 31, 2025), not a US approval.
Are vaccines or lab tests required before Rystiggo?
None is a precondition in the December 2025 label: there is no REMS, no required vaccine series and no scheduled lab, and UCB states there is no pre-treatment vaccination requirement. The label asks prescribers to evaluate age-appropriate vaccines before each new cycle, says live vaccines are not recommended during treatment, and says to delay any dose during active infection. Payers may still want a serum IgG; FEP requires 5.5g/L or more, the Study 1 entry threshold.
What do insurers ask for to approve Rystiggo?
The FEP policy 5.85.050, effective October 1, 2026 and citing the December 2025 label, asks for age 18 or older, positive anti-AChR or anti-MuSK antibodies, MGFA class II to IVa, MG-ADL of 3 or more (3 or more non-ocular) or QMG above 9, IgG of 5.5g/L or more and one failed conventional agent. It approves 6 months, then 12 months on a 2-point MG-ADL or QMG improvement without unacceptable toxicity.
Free email alert
Get an email when the Rystiggo label changes
One email the day the FDA revises the Rystiggo prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Rystiggo only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use, prescribing information, revised December 2025 (DailyMed SPL version 11), UCB, via DailyMed, 2026-10-23.
- RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use, prescribing information, revised 12/2025 (BLA 761286/S-007), FDA, Drugs@FDA, 2025-12-09.
- RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use, prescribing information, revised 6/2024 (BLA 761286/S-001), FDA, Drugs@FDA, 2024-06-14.
- Dosing and Administration of RYSTIGGO® Infusion For gMG, UCB, 2026-11-07.
- RYSTIGGO Frequently Asked Questions, UCB, 2026-11-07.
- Cost and Insurance Information for RYSTIGGO® (rozanolixizumab-noli), UCB, 2026-11-07.
- ONWARD® Support For RYSTIGGO Treatment, UCB, 2026-11-07.
- ONWARD® | Care Coordinators - Treatment Preparation, UCB, 2026-11-07.
- ONWARD® | Finances - Insurance and RYSTIGGO, UCB, 2026-11-07.
- Start Form for RYSTIGGO® (rozanolixizumab-noli) Injection For Subcutaneous Use (US-RZ-2600436), UCB, 2026-07-07.
- How to Acquire RYSTIGGO, UCB, 2026-07-16.
- Coding and Billing Guide for the use of RYSTIGGO (rozanolixizumab-noli) in adult patients with generalized myasthenia gravis (gMG), UCB, 2024-07-15.
- Pharmacy Policy 5.85.050, Rystiggo (rozanolixizumab-noli), Blue Cross Blue Shield Federal Employee Program, 2026-10-01.
- RYSTIGGO®▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods, UCB, 2025-01-31.
- BLA 761286/S-007 supplement approval letter, pregnancy exposure registry and postmarketing herpes zoster, FDA, 2025-12-09.
- BLA 761286 approval letter, Rystiggo (rozanolixizumab-noli) injection, FDA, 2023-06-26.
A reference drawn from the October 23, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.